Facet is on the cutting edge again!
Congratulations to Dr. Bill Hodnick on his upcoming publication.
“Potential Use of the Mitomycin Analogue BMY25282 as a Superior Hypoxia Targeted Anticancer Agent”
Facet Life Sciences Recognizes Bill Hodnick’s Achievements
